Catalent prices IPO at $20.50, midpoint of the range


Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, raised $871 million by offering 42.5 million shares (100% primary) at $20.50, the midpoint of the $19-$22 range. At its offer price, Catalent commands a market cap of $2.5 billion and an EV of $4.4 billion. Catalent will list on the NYSE under the symbol CTLT. Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman Sachs, Jefferies & Co. and Deutsche Bank all acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: News Headlines , IPOs

Referenced Stocks: CTLT

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by